Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Ear and labyrinth disorders

  • 37 clinical trials
  • 14 recruiting
  • 43 conditions
  • 18 countries

Conditions in this area

43 conditions with trials, the busiest first

Deafness8Alport's syndrome6Paraganglion neoplasm5Deafness neurosensory4Phaeochromocytoma4Otitis media3Vestibular disorder3Focal segmental glomerulosclerosis2Meniere's disease2Neuroendocrine tumour2Tinnitus2Usher's syndrome2Wolfram syndrome2Acoustic neuroma1Bile duct cancer1Chronic kidney disease1Chronic rhinosinusitis with nasal polyps1Colorectal cancer1Deafness bilateral1Deafness traumatic1Dizziness1Ductal adenocarcinoma of pancreas1Ear discomfort1Endolymphatic hydrops1+19

Clinical trials in Ear and labyrinth disorders

37 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

37 clinical trials

Endometrial cancer+12

Recruiting

A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Vestibular disorder

Recruiting

A study to evaluate the use of levothyroxine sodium in patients with sudden onset of dizziness caused by inner ear issues.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Levothyroxine Sodium
  • Sponsor:Klinikum Der Universitat Munchen AöR

Vestibular disorder

Recruiting

A Study of Prednisolone Compared to Placebo for Patients with Vestibular Neuritis to Evaluate Effects on Balance and Dizziness Symptoms

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Region Vaesterbotten

Tinnitus

Recruiting

Study on Botulinum Toxin A for Tinnitus in Patients with Bruxism or Jaw Muscle Pain

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Sorlandsklinikken

Deafness neurosensory+1

Recruiting

Study on the Effects of Intracochlear Triamcinolone Acetonide for Patients with Persistent Sudden Sensorineural Hearing Loss After Unsuccessful Conservative Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Triamcinolone Acetonide
  • Sponsor:Medical University Of Vienna

Deafness

Recruiting

Study on Long-Term Safety of AAVAnc80-hOTOF Gene Therapy for Patients with Sensorineural Hearing Loss Due to Otoferlin Gene Mutations

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Aavanc80-3'Hotof
  • Sponsor:Akouos Inc.

Otitis media+1

Recruiting

Study on Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Amsterdam UMC Stichting

Paraganglion neoplasm

Recruiting

Study on Using Exenatide PET/CT Imaging for Detecting Paragangliomas in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Exenatide
  • Sponsor:Stichting Radboud University Medical Center

Alport's syndrome

Recruiting

Study on Dapagliflozin for Slowing Kidney Disease in Adolescents and Young Adults with Alport Syndrome

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsmedizin Goettingen

Glomerulonephritis minimal lesion+3

Recruiting

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sparsentan
  • Sponsor:Travere Therapeutics Inc.

Deafness

Recruiting

Study on DB-OTO for Safety and Tolerability in Infants and Children with Genetic Hearing Loss

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Db-Oto-3
  • Sponsor:Regeneron Pharmaceuticals Inc.

Ear discomfort+11

Recruiting

Study on Meniere's Disease: Comparing Methylprednisolone and Placebo for Patients with Unilateral Meniere's Disease

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Substances studied in this area

The therapies tested most often in Ear and labyrinth disorders trials.

Prednisolone3 clinical trialsAavanc80-3'Hotof2 clinical trialsAavanc80-5'Hotof2 clinical trialsOxygen2 clinical trialsPlacebo2 clinical trialsSodium Chloride2 clinical trialsTriamcinolone Acetonide2 clinical trials6-Fluoro-9-Methyl-9H-Pyrido[3,4-B]-Indole1 clinical trialAbiraterone Acetate1 clinical trial
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.